Cellebrite DI reported third-quarter results above key estimates on November 12, 2026, yet its shares traded down about 14% after the same report trimmed full-year revenue guidance again. Investors who lost money in the reversal may have legal rights. NEW YORK, Nov. 13, 2026 /PRNewswire/...